CALL 1-877-30-AUVIQ

Hospitalizations from anaphylaxis rose from 21.0 to 25.1 per million population between 1999 and 2009.1

Asset 171999200925.1per million21.0per million

Hospitalizations from anaphylaxis
Based on Nationwide Inpatient Sample database.

ED visits for anaphylaxis among children (< 21 years old) in the US increased 3x between 2008 and 2016.5

Why do food allergies develop?

Watch what these opinion leaders have to say

Visit our library to learn more from other opinion leaders.

Visit our library to learn more from other opinion leaders.

Studies have shown that teens and young adults are at the greatest risk for fatalities due to food-induced anaphylaxis.6,7

Based on a survey of 174 participants 13-21 years old, peer pressure and increased risk-taking related to allergen exposure are challenges to their self-management of food allergies.6

The increased risk in this age may be related to7:

  • Decreased parental supervision
  • Increased risk-taking

In one study (N = 174), more than half of teens and young adults exhibited risk-taking behaviors related to food allergies6

54% admitted to eating a small amount of an allergen-containing food Reasons for eating allergen-containing foods

Internet survey of persons 13 to 21 years old with food allergy in North America in 2006.

Allergic emergencies can happen outside the comfort and familiarity of home, in places like8-12:

SCHOOLS

RESTAURANTS

FRIENDS' HOMES

CAMPS

In one study at two metropolitan hospitals (N = 150), nearly one-third of food-related anaphylaxis in children ages 6 to 11 years presenting to the emergency department occurred away from home.13

31percentCreated with Sketch.

According to a survey of 2040 school nurses, staff that may be allowed to administer epinephrine include14:

Delayed epinephrine administration in anaphylaxis is associated with an increased risk of hospitalization and poor outcomes, including death.12,20-23

What might stop your patients from using their epinephrine auto-injector during anaphylaxis?

≤50% of children who had an epinephrine auto-injector used it

Data are from North American studies.11,24-26

Anaphylaxis is an allergic emergency that requires immediate medical care after prompt administration of epinephrine.

Antihistamines do not treat all the symptoms of anaphylaxis17,27,28

Watch this doctor explain

Visit our library to learn more from other opinion leaders.

Visit our library to learn more from other opinion leaders.

Discover the features of AUVI-Q to see how they can fit in the lives of your patients with life-threatening allergies.

EXPLORE DEVICE
INDICATION and IMPORTANT SAFETY INFORMATION
Read More
INDICATION

AUVI-Q® (epinephrine injection, USP) is indicated in the emergency treatment of allergic reactions (Type I) including anaphylaxis to allergens, idiopathic and exercise-induced anaphylaxis. AUVI-Q is intended for patients with a history of anaphylactic reactions or who are at increased risk for anaphylaxis.

IMPORTANT SAFETY INFORMATION

AUVI-Q is intended for immediate self-administration as emergency supportive therapy only and is not a substitute for immediate medical care. In conjunction with the administration of epinephrine, the patient should seek immediate medical or hospital care. Each AUVI-Q contains a single dose of epinephrine for single-use injection. More than two sequential doses of epinephrine should only be administered under direct medical supervision. Since the doses of epinephrine delivered from AUVI-Q are fixed, consider using other forms of injectable epinephrine if doses lower than 0.1 mg are deemed necessary.

AUVI-Q should ONLY be injected into the anterolateral aspect of the thigh. Do not inject intravenously, or into buttock, digits, hands, or feet. Instruct caregivers to hold the leg of young children and infants firmly in place and limit movement prior to and during injection to minimize the risk of injection-related injury.

Rare cases of serious skin and soft tissue infections have been reported following epinephrine injection. Advise patients to seek medical care if they develop any of the following symptoms at an injection site: redness that does not go away, swelling, tenderness, or the area feels warm to the touch.

Epinephrine should be administered with caution to patients with certain heart diseases, and in patients who are on medications that may sensitize the heart to arrhythmias, because it may precipitate or aggravate angina pectoris and produce ventricular arrhythmias. Arrhythmias, including fatal ventricular fibrillation, have been reported in patients with underlying cardiac disease or taking cardiac glycosides or diuretics. Patients with certain medical conditions or who take certain medications for allergies, depression, thyroid disorders, diabetes, and hypertension, may be at greater risk for adverse reactions. Common adverse reactions to epinephrine include anxiety, apprehensiveness, restlessness, tremor, weakness, dizziness, sweating, palpitations, pallor, nausea and vomiting, headache, and/or respiratory difficulties.

Please see the full Prescribing Information and the Patient Information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

I am at least 18 years old and I authorize Kaléo and its contractors to use, disclose, and/or transfer the personal information I supply (1) to contact me and provide me with informational and marketing materials and clinical trial opportunities related to my condition or treatment by any means of communication, including but not limited to text, e-mail, mail, or telephone; (2) to help Kaléo improve, develop, and evaluate products, services, materials and programs related to my condition or treatment; (3) to enroll me in and provide me with AUVI-Q related programs and services that I may select or refuse at any time; (4) to disclose my enrollment and use of these services to my healthcare providers and insurers; and (5) to use my information that cannot identify me for scientific and market research.

To learn more about the Kaléo Privacy Notice, click here.

To cancel or request a copy of this authorization, please contact us at 1-877-30-AUVIQ. I understand that if I cancel I may not be entitled to receive AUVI-Q related programs and services.

The health information contained herein is provided for general educational purposes only. Please consult with your healthcare professional if you have any questions about your health or treatment.

EXIT

You are leaving www.auvi-q.com

Please understand that AUVI-Q is not responsible for how your information is processed or used on non-AUVI-Q sites. Also note that providing links to non-AUVI-Q sites is not an endorsement of the other site by AUVI-Q or any of its employees. And finally, be aware that the primary protection provided on our site may not be available on an external link.

PROCEED

Kaléo Patient Assistance Program

Kaléo, the maker of AUVI-Q, understands the importance of having emergency medications available to patients. We also recognize that some patients may have financial difficulties that prevent them from obtaining these needed medications.

Through the Kaléo Patient Assistance Program, patients who are experiencing financial difficulties may be able to receive AUVI-Q at no cost.

To be eligible for assistance, a patient must:

Patients who are eligible for Medicaid coverage may be eligible for assistance to receive AUVI-Q at no cost.

DOWNLOAD FORM

INDICATION
AUVI-Q® (epinephrine injection, USP) is indicated in the emergency treatment of allergic reactions (Type I) including anaphylaxis to allergens, idiopathic and exercise-induced anaphylaxis. AUVI-Q is intended for patients with a history of anaphylactic reactions or who are at increased risk for anaphylaxis.

IMPORTANT SAFETY INFORMATION
AUVI-Q is intended for immediate self-administration as emergency supportive therapy only and is not a substitute for immediate medical care. In conjunction with the administration of epinephrine, the patient should seek immediate medical or hospital care. Each AUVI-Q contains a single dose of epinephrine for single-use injection. More than two sequential doses of epinephrine should only be administered under direct medical supervision. Since the doses of epinephrine delivered from AUVI-Q are fixed, consider using other forms of injectable epinephrine if doses lower than 0.1 mg are deemed necessary.

AUVI-Q should ONLY be injected into the anterolateral aspect of the thigh. Do not inject intravenously, or into buttock, digits, hands, or feet. Instruct caregivers to hold the leg of young children and infants firmly in place and limit movement prior to and during injection to minimize the risk of injection-related injury.

Rare cases of serious skin and soft tissue infections have been reported following epinephrine injection. Advise patients to seek medical care if they develop any of the following symptoms at an injection site: redness that does not go away, swelling, tenderness, or the area feels warm to the touch.

Epinephrine should be administered with caution to patients with certain heart diseases, and in patients who are on medications that may sensitize the heart to arrhythmias, because it may precipitate or aggravate angina pectoris and produce ventricular arrhythmias. Arrhythmias, including fatal ventricular fibrillation, have been reported in patients with underlying cardiac disease or taking cardiac glycosides or diuretics. Patients with certain medical conditions or who take certain medications for allergies, depression, thyroid disorders, diabetes, and hypertension, may be at greater risk for adverse reactions. Common adverse reactions to epinephrine include anxiety, apprehensiveness, restlessness, tremor, weakness, dizziness, sweating, palpitations, pallor, nausea and vomiting, headache, and/or respiratory difficulties.

Please see the full Prescribing Information and the Patient Information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Pricing Philosophy for AUVI-Q® (epinephrine injection, USP)

As a company founded by patients with life-threatening allergies, we take our commitment to the needs of patients and their families very seriously. In this era of high deductible health plans, many patients find it harder than ever to afford their medications. We are committed to ensuring thatpatients with commercial insurance, or those facing financial hardship, should be able to obtain our potentially lifesaving products for little to no out-of-pocket cost.

Our Beliefs:
For us, the patient always comes first. We believe the most important price is the price to the patient. We believe that patients with life-threatening conditions deserve fair access to the latest medicines that offer technological innovations that address their medical needs. We believe that when a healthcare practitioner prescribes AUVI-Q, patients should be able to fill their prescription without high out-of-pocket costs.

Our Commitment to Access and Affordability:
We have seen firsthand in this current healthcare system the very real challenges patients are facing in being able to access and afford potentially lifesaving medicines. Similar to our product innovation process, our AUVI-Q patient access program has been built to solve for some of these challenges and help focus on what matters most... access and affordability to AUVI-Q for patients.

Our Commitment to AUVI-Q Manufacturing and Quality:
Kaléo is committed to the highest standards of product and manufacturing quality. Final manufacturing and assembly of AUVI-Q is conducted in the United States on a 100% automated robotic production line with more than 100 automated quality checks on each and every product.

Patients can be confident in our approach to design quality into AUVI-Q and incorporate quality into every aspect of the manufacturing process.

References

Terms and Conditions

Only valid for commercially insured patients in the 50 United States and DC through the direct delivery service and/or designated retail pharmacies. Not eligible if prescriptions are paid for in part/full by state or federally funded program(s), like Medicare Part D, Medicaid, Vet. Aff., Dept. of Def., or Tricare, and where prohibited by law. OFFER IS NOT INSURANCE. Offer cannot be sold, purchased, traded, transferred, and cannot be combined with any other offer. Cash discount cards are not commercial payers and are not eligible to be used for this program. Offer provided by Kaléo, and it may change at any time without notice.

Call 1-877-30-AUVIQ for questions regarding offer eligibility.

Thank you!

We look forward to staying in touch.

Thank you!

Your request has been received. We will follow up with details shortly.

AUVI-Q® (epinephrine injection, USP) administers epinephrine in 3 steps.29